The post HBAR Price Prediction: Targets $0.16 by January End Despite Technical Headwinds appeared on BitcoinEthereumNews.com. Joerg Hiller Jan 15, 2026 10:09The post HBAR Price Prediction: Targets $0.16 by January End Despite Technical Headwinds appeared on BitcoinEthereumNews.com. Joerg Hiller Jan 15, 2026 10:09

HBAR Price Prediction: Targets $0.16 by January End Despite Technical Headwinds



Joerg Hiller
Jan 15, 2026 10:09

Hedera (HBAR) faces mixed signals at $0.12 with analyst targets of $0.16 by month-end, though bearish momentum and neutral RSI suggest cautious approach needed.

HBAR Price Prediction Summary

• Short-term target (1 week): $0.13-$0.14
• Medium-term forecast (1 month): $0.14-$0.16 range
• Bullish breakout level: $0.13
• Critical support: $0.11

What Crypto Analysts Are Saying About Hedera

Recent analysis from Blockchain.News presents an optimistic Hedera forecast despite current market conditions. According to their January 13th report, “HBAR shows neutral momentum at $0.12 with analysts targeting $0.16 by January end,” representing a potential 31% upside from current levels.

Their earlier analysis on January 12th reinforced this bullish stance, stating “Hedera (HBAR) shows bullish momentum despite recent decline. Technical analysis points to $0.16 target by month-end with key support at $0.11.” This $0.16 target appears consistently across recent professional assessments.

While specific predictions from individual crypto analysts are limited in recent days, the consensus among institutional observers points toward modest upward momentum for HBAR through January’s remainder.

HBAR Technical Analysis Breakdown

Current technical indicators present a mixed picture for this HBAR price prediction. Trading at $0.12 with a -2.94% daily decline, Hedera sits precisely at multiple moving average confluence points, suggesting a critical decision zone.

The RSI reading of 51.05 indicates neutral momentum, neither oversold nor overbought conditions. This neutral positioning often precedes significant directional moves, making the current level pivotal for future price action.

MACD signals show bearish divergence with a histogram reading of -0.0000, indicating weakening upward momentum. The MACD line at -0.0002 below its signal line suggests sellers maintain slight control in the near term.

Bollinger Bands analysis reveals HBAR positioned at 0.60 between bands, closer to the upper boundary ($0.13) than lower support ($0.11). This positioning suggests room for downward movement before reaching oversold conditions.

Daily volatility measured by ATR stands at $0.01, indicating relatively stable price swings that support controlled entry and exit strategies for traders.

Hedera Price Targets: Bull vs Bear Case

Bullish Scenario

The bullish Hedera forecast centers on breaking through immediate resistance at $0.13, which coincides with the Bollinger Band upper boundary and 24-hour trading high. A decisive close above $0.13 could trigger momentum toward the $0.16 analyst target.

Technical confirmation would require RSI moving above 60 and MACD histogram turning positive. Strong support at $0.12 (current moving average cluster) provides a solid foundation for upward moves.

Volume dynamics show $22.9 million in daily trading, sufficient for supporting moderate price appreciation. The $0.16 target represents the 200-day moving average area at $0.19, making it a logical resistance zone.

Bearish Scenario

Bearish risks emerge if HBAR fails to hold the $0.12 support cluster. A break below this level could target the Bollinger Band lower boundary at $0.11, representing the critical support level identified in recent analysis.

The negative MACD momentum supports potential downside, particularly if broader crypto markets face headwinds. Loss of $0.11 support could extend declines toward psychological support near $0.10.

Risk factors include the significant distance from the 200-day moving average at $0.19, indicating HBAR remains in a longer-term downtrend despite recent stabilization.

Should You Buy HBAR? Entry Strategy

For this HBAR price prediction to materialize, strategic entry points emerge at current levels near $0.12, particularly on any slight pullbacks toward $0.118-$0.12. This range offers favorable risk-reward ratios given the proximity to technical support.

Conservative traders might await a clear breakout above $0.13 with volume confirmation before establishing positions. This approach sacrifices early entry benefits but reduces false breakout risks.

Stop-loss placement below $0.11 provides reasonable protection while allowing for normal market volatility. Position sizing should account for the 8-10% potential downside to this stop level.

Risk management becomes crucial given the mixed technical signals. Consider scaling into positions rather than committing full allocations immediately.

Conclusion

This HBAR price prediction suggests modest optimism tempered by technical caution. The $0.16 target by month-end appears achievable based on analyst consensus, representing reasonable expectations given current market positioning.

However, bearish MACD momentum and neutral RSI readings suggest this forecast requires careful monitoring of key technical levels. Success depends largely on maintaining support above $0.12 and achieving sustainable breaks above $0.13.

Traders should approach this Hedera forecast with appropriate risk management, as cryptocurrency markets remain highly volatile and unpredictable. Past performance and technical analysis do not guarantee future price movements.

Disclaimer: This analysis is for educational purposes only and should not be considered financial advice. Cryptocurrency investments carry substantial risk of loss.

Image source: Shutterstock

Source: https://blockchain.news/news/20260115-price-prediction-hbar-targets-016-by-january-end-despite

Market Opportunity
Hedera Logo
Hedera Price(HBAR)
$0.1176
$0.1176$0.1176
-2.41%
USD
Hedera (HBAR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26